WuXi Biologics (China) and Inhibrx (USA), a biopharmaceutical company, announced that the companies have entered into an exclusive partnership for the GMP manufacturing of certain of Inhibrx’s protein-based therapeutics.
The agreement showcases the expansive biologics pipeline of Inhibrx and the world leading technical expertise and capabilities of WuXi Biologics as the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.
Inhibrx is a clinical-stage biotechnology company developing a diverse pipeline of novel protein-based therapeutics for underserved patient populations. Inhibrx’s novel single domain antibody (sdAb) platforms substantially improve upon conventional monoclonal antibody (mAb) and fusion protein approaches, enabling best in class therapeutics that address complex target biology beyond the capacity of conventional approaches. Inhibrx has collaborations with Celgene and the Alpha-1 Foundation, and has received awards from several granting agencies, including NIH, NIAID and CARB-X.
Under the terms of the agreement, Inhibrx will subject to certain limitations, exclusively use WuXi Biologics for GMP manufacturing of its human biologic therapeutics for all projects to be initiated within next 3 years which Inhibrx plans to first initiate clinical trials outside of China.